Psychopharmacology in Malabsorption & Short Gut

← Back to Chapters

Renal and hepatic impairment change how a drug leaves the body. Malabsorption changes something we almost never think about because it usually just works: whether the drug gets in at all. When the gut is short, rerouted, inflamed, or moving too fast — after bariatric surgery, in short bowel syndrome, in active inflammatory bowel or celiac disease, with an ileostomy, or through a feeding tube — the oral route stops being the reliable default. The failure is quiet: there is no toxic level to measure and no encephalopathy to see, just a patient who mysteriously stops responding, or whose levels drift, on a dose that should work. This chapter explains where oral absorption breaks, and then gives the two families of fix: change the formulation, or bypass the gut entirely.

Absorption: the forgotten pharmacokinetic step

Oral bioavailability is the product of several things going right in sequence: the tablet disintegrates and the drug dissolves (which for many drugs needs gastric acid, and for lipophilic drugs needs bile), the dissolved drug meets an adequate absorptive surface for long enough to cross it, and it survives first-pass metabolism. Most of that absorption happens in the proximal small intestine. Altered GI anatomy attacks these steps directly, and because the result is under-exposure rather than toxicity, it tends to be missed — a patient labeled a "non-responder" or "non-adherent" may simply not be absorbing the drug.

The mechanisms of malabsorption

Reduced absorptive surface (short gut). Short bowel syndrome — from resection for Crohn's disease, mesenteric ischemia, volvulus, or trauma — removes absorptive real estate. The clinical impact depends on how much bowel remains, which segments (the ileum has specialized functions, including bile-salt and B12 handling), and whether the colon is in continuity. Less surface plus faster transit means less drug crosses.

Rapid transit. Diarrhea, an ileostomy, or a surgically shortened path reduces the contact time between drug and mucosa. Extended-release products, engineered to release over many hours, are especially vulnerable — they can pass into the stoma bag or stool substantially intact.

Loss of gastric acid and altered pH. Bariatric procedures and chronic acid suppression reduce the acidic environment some drugs need to dissolve; the higher, more variable pH degrades the reliability of dissolution for acid-dependent agents.

Loss of bile availability. Lipophilic drugs — a category that includes many psychotropics — depend on bile for solubilization. Procedures that reroute or reduce bile exposure to ingested drug (as gastric bypass does by excluding the duodenum) impair uptake of fat-soluble agents.

Formulation failure. Sustained-release, extended-release, long-acting oral, and enteric-coated formulations all assume a normal transit time and pH to release their payload gradually. When that assumption breaks, so does the release — reducing efficacy in a way that switching to an immediate-release version of the same drug usually corrects.

Bariatric surgery: the common and instructive case

Weight-loss surgery is now common, patients who have it frequently need psychotropics, and it illustrates every mechanism above — while adding two of its own: a moving target as weight falls, and a lithium-specific hazard.

The procedure matters. Roux-en-Y gastric bypass both restricts the stomach and reroutes the small bowel to exclude the duodenum and proximal jejunum — precisely where much absorption and bile mixing occur — so it has the largest and least predictable effect on drug uptake. Sleeve gastrectomy is primarily restrictive and alters gastric volume and acid but preserves intestinal routing, so its effect is generally smaller. Purely restrictive or reversible procedures differ again.

Formulation first. The most reliable single intervention is to convert extended/sustained-release and enteric-coated psychotropics to immediate-release equivalents, because those formulations show compromised dissolution and reduced, erratic absorption after surgery. Agents that have specifically been flagged for possibly reduced absorption and efficacy after bariatric surgery include lamotrigine, olanzapine, and quetiapine, but the principle is general.

A moving target. In the months after surgery, rapid weight loss changes body composition and the volume of distribution of lipophilic and hydrophilic drugs alike, at the same time as absorption is recovering from the acute post-operative state. Dose requirements therefore change over time, not once — the right posture is scheduled reassessment rather than a single post-op adjustment.

Short bowel, ostomies, and feeding tubes

Short bowel syndrome compounds reduced surface with rapid transit and, often, dependence on parenteral nutrition; oral absorption of any given drug can be markedly and unpredictably reduced, and immediate-release liquid or dissolved formulations are preferred over solids and extended-release. Ileostomy patients may pass extended-release tablets whole into the bag — a visible clue — and again do better with immediate-release. For patients fed by enteral tube, extended-release and enteric-coated products generally cannot be crushed (crushing an ER tablet can dump the whole dose at once, a dangerous over-delivery, and destroys the enteric protection), so an immediate-release, liquid, or dispersible formulation is chosen instead, and drug administration is separated in time from continuous feeds that can bind it.

The two families of fix

Change the formulation. The first and simplest move is to keep the same drug but choose a form that does not depend on a long, intact, acidic, bile-rich transit: immediate-release instead of extended-release; a liquid/solution; or an orally disintegrating tablet (available for olanzapine, risperidone, aripiprazole, mirtazapine and others) that begins dissolving in the mouth. This solves formulation-failure and some dissolution problems, though it does not overcome a genuine loss of absorptive surface.

Bypass the gut. When oral uptake is fundamentally unreliable, deliver the drug by a route that skips intestinal absorption altogether:

Monitoring: absorption problems are inferred

Because malabsorption produces under-exposure rather than a measurable toxin, the clinician has to look for it deliberately. Where therapeutic drug monitoring exists — lithium, valproate, some TCAs, clozapine — a lower-than-expected level on an adequate dose is the most direct evidence. Otherwise the signal is clinical: loss of a previously good response, or a maintenance patient who relapses without a clear psychosocial explanation, in the context of a gut that has been altered. The response is to reconsider formulation and route before simply escalating the oral dose, which in a genuinely malabsorptive gut may never reach target however high it is pushed.

This chapter completes the special-population set alongside renal impairment, hepatic impairment, and long QT syndrome; see Long-Acting Injectables for the maintenance option that most cleanly sidesteps the gut, and Pharmacokinetics for the absorption fundamentals.

References & Further Reading

1. Be prepared to adjust dosing of psychotropics after bariatric surgery. Current Psychiatry.
2. Azran C, et al. Oral drug therapy following bariatric surgery: an overview of fundamentals, literature and clinical recommendations. Obes Rev.
3. Changes in antidepressant absorption after metabolic and bariatric surgery: a review. (2025.)
4. Pironi L, et al. ESPEN guideline on chronic intestinal failure in adults (short bowel syndrome). Clin Nutr.
5. Titus R, et al. Medication management in patients with short bowel syndrome. Nutr Clin Pract.
6. White JR, Case DA. Enteral feeding tubes and drug administration: avoiding common errors. (Clinical review.)

This chapter is an educational review for clinicians and trainees. It reflects evidence current as of September 2026 and should be validated against current product labeling, pharmacy guidance, and institutional protocols; it is not a substitute for clinical judgment.